Diethyltryptamine
| Clinical data | |
|---|---|
| Other names | DET; N,N-Diethyltryptamine; N,N-DET; T-9; T9 |
| Routes of administration | Oral, inhalation (smoking), intramuscular, intravenous, subcutaneous |
| Drug class | Non-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | Oxidative deamination (MAO-A), N-oxidation, N-dealkylation |
| Metabolites |
|
| Onset of action |
|
| Duration of action | 2–4 hours |
| Excretion | urine |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H20N2 |
| Molar mass | 216.328 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 169 to 171 °C (336 to 340 °F) |
| |
| |
| (verify) | |
Diethyltryptamine (DET), also known as N,N-diethyltryptamine or T-9, is a psychedelic drug of the tryptamine family closely related to dimethyltryptamine (DMT). It is taken orally, but can also be used by parenteral routes.
The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor among others. It has not been found to occur endogenously. DMT is a close structural homologue of DMT and dipropyltryptamine (DPT). Other analogues of DET include 4-HO-DET (ethocin), ethocybin (4-PO-DET), and 5-MeO-DET.
DET was first synthesized in 1956 by Stephen Szára and subsequently described in material published in 1957. More systematic studies were reported later by Szára and colleagues and independently by Böszörményi and colleagues.